|
A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children Clinical research trials and A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children. A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children clinical trial. Subjects often receive the most expert healthcare possible for their A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children  A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children
A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Roxane Laboratories
Synopsis: Monotherapy phase: To evaluate and compare the safety, tolerance, pharmacokinetics, and preliminary activity of nevirapine administered alone in mildly to moderately symptomatic HIV-infected children ages 2 months to less than 18 years; to evaluate and compare the safety, tolerance, and pharmacokinetics of nevirapine in HIV-infected children ages 1 day to less than 2 months. Combination therapy phase: To evaluate and compare the safety, tolerance, pharmacokinetics, and preliminary activity of nevirapine administered in combination with zidovudine (AZT) in mildly to moderately symptomatic HIV-infected children ages 2 months to less than 18 years. Compounds with reverse transcriptase inhibitory activity that are more potent and less toxic than the nucleoside analogues are needed. Nevirapine (BI-RG-587) has shown in vitro inhibitory activity against HIV-1reverse transcriptase and has shown a synergistic inhibition of HIV-1 replication when combined with zidovudine (AZT) in a plaque reduction assay.
Details: Compounds with reverse transcriptase inhibitory activity that are more potent and less toxic than the nucleoside analogues are needed. Nevirapine (BI-RG-587) has shown in vitro inhibitory activity against HIV-1 reverse transcriptase and has shown a synergistic inhibition of HIV-1 replication when combined with zidovudine (AZT) in a plaque reduction assay. Sixty mildly to moderately symptomatic HIV-infected children (five patients in each of four age groups) will receive oral nevirapine at 1 of 3 doses for 168 days. If preliminary activity is demonstrated and toxicity is acceptable after 84 days of treatment in the three oldest age groups (ages 2 months - less than 2 years, ages 2 years - less than 13 years, and ages 13 years - less than 18 years), children ages 1 day - less than 2 months will receive one of the three doses of nevirapine. Additionally, 15 additional patients (five in each of three age groups) will receive zidovudine in combination with nevirapine. At the end of 24 weeks of combination therapy, patients discontinue zidovudine for 2 weeks while remaining on nevirapine, in order for pharmacokinetic sampling to be done. Children will be enrolled sequentially by decreasing age and increasing nevirapine dose.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /17 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - IV gammaglobulin therapy. - Medications for PCP prophylaxis (e.g., TMP / SMX, dapsone, aerosolized and IV pentamidine). - Fluconazole. Patients must have: - HIV infection. A positive Polymerase Chain Reaction (PCR) is not acceptable as the sole evidence of HIV infection. Three out of five children in each age and dose group must have a serum p24 antigen level of 70 pg/ml or greater and/or a plasma viral titer of 50 TCID/ml or greater prior to study entry. - Ability to be followed by their original trial center for the duration of the trial. - Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Lymphocytic interstitial pneumonitis if steroid-dependent or requiring supplemental oxygen or with a pretreatment paO2 < 70 mm Hg. - Opportunistic or serious bacterial infections within 28 days prior to entry. - Demonstrated intolerance to zidovudine prior to administration of nevirapine (in patients enrolled in the combination therapy phase of the study). - CDC classification of P-2D (secondary infectious diseases) and/or P-2E (secondary cancers). - Pre-existing malignancies. Concurrent Medication: Excluded: - Other approved or investigational antiretroviral agents. - All other investigational agents (except fluconazole). - Glucocorticoids and steroid hormones. - Dicumarol, warfarin, and other anticoagulants. - Digitoxin. - Valproic acid. - Tolbutamide. - Doxycycline. - Chloramphenicol. - Isoniazid. - Phenobarbital and other barbiturates. - Hepatotoxic drugs. Patients with prior participation in this trial are excluded. Prior Medication: Excluded: - More than 6 weeks of prior zidovudine (AZT) therapy or more than 6 weeks of any other antiretroviral therapy. Excluded within 7 days prior to study entry: - AZT (in monotherapy groups only). Excluded within 4 weeks prior to study entry: - Other approved or investigational antiretroviral agents. - All other investigational agents. - Glucocorticoids and steroid hormones. - Dicumarol, warfarin, and other anticoagulants. - Digitoxin. - Valproic acid. - Tolbutamide. - Doxycycline. - Chloramphenicol. - Isoniazid. - Phenobarbital and other barbiturates. Active alcohol or drug abuse to impair compliance with the protocol.
Total Enrollment: 35
Location and Contact Information:
Overall Study Official:
JSullivan, Study Chair,
Univ of Connecticut Health Ctr / Pediatrics
Farmington, Connecticut, 06032
United States
UCLA Med Ctr / Pediatrics
Los Angeles, California, 90095
United States
Baystate Med Ctr of Springfield
Springfield, Massachusetts, 01199
United States
Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl
Newark, New Jersey, 071072198
United States
Univ of Miami (Pediatric)
Miami, Florida, 33161
United States
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, 900331079
United States
Univ of Massachusetts Med Ctr / Biotech II
Worcester, Massachusetts, 01605
United States
Additional Information:
Study ID Numbers: ACTG 180; 882
Study Start Date:
Record last reviewed: April 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001111
Other Hiv Infections Studies:
1. A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis (Diarrhea Caused by the Parasite Cryptosporidium)
2. Cause of Focal Segmental Glomerulosclerosis
3. When to Start Anti-HIV Drugs in Patients with Opportunistic Infections
4. Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
5. Rapid HIV Tests for Women Late in Pregnancy and During Labor
Related Studies:
Other HIV Infections Clinical Trials
Other Connecticut Clinical Trials
Other Farmington Clinical Trials
A Study of Nevirapine Used Alone or in Combination with AZT in HIV-1-Infected Children
|
|
|
|
|
|
|
|
